Keith T. Flaherty
Harvard University · 1,807 works · 122,707 citations · h-index 147
Top works
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Final Version of 2009 AJCC Melanoma Staging and Classification
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
- Genomic Classification of Cutaneous Melanoma
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
- RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial